The use of Faecal Microbiota Transplantation (FMT) in Europe: A Europe-wide survey.
The use of Faecal Microbiota Transplantation (FMT) in Europe: A Europe-wide survey.
复制标题
DOI：
10.1016/j.lanepe.2021.100181
复制
发表时间：
2021-10
期刊：
影响因子：
--
通讯作者：
Hvas CL
中科院分区：
文献类型：
--
作者：
Baunwall SMD;Terveer EM;Dahlerup JF;Erikstrup C;Arkkila P;Vehreschild MJ;Ianiro G;Gasbarrini A;Sokol H;Kump PK;Satokari R;De Looze D;Vermeire S;Nakov R;Brezina J;Helms M;Kjeldsen J;Rode AA;Kousgaard SJ;Alric L;Trang-Poisson C;Scanzi J;Link A;Stallmach A;Kupcinskas J;Johnsen PH;Garborg K;Rodríguez ES;Serrander L;Brummer RJ;Galpérine KT;Goldenberg SD;Mullish BH;Williams HR;Iqbal TH;Ponsioen C;Kuijper EJ;Cammarota G;Keller JJ;Hvas CL
粪便微生物群移植（FMT）是一种新兴的治疗方式，但其目前的临床应用和组织尚不清楚。我们的目的是描述FMT在欧洲的临床使用、实施和潜力。我们邀请欧洲理事会成员国内所有以医院为基础的FMT中心回答一份基于网络的问卷，内容涉及其2019年的临床活动、组织和FMT监管。从clinicaltrials.gov注册的试验和欧洲联合胃肠病学（UEG）粪便库和FMT工作组中确定了应答者。2019年，来自17个国家的31家FMT中心共报告了1，874例（中位数25，四分位数10-64）FMT手术; 1，077例（57%）以艰难梭菌感染（CDI）为适应症，791例（42%）为实验适应症，6例（0.3%）未说明。根据人群规模调整后，每100，000人中有0.257人因CDI接受FMT，每100，000人中有0.189人因实验适应症接受FMT。欧洲每年估计有12，400（6，100 - 28，500）例多发性、复发性CDI和FMT适应症病例，目前欧洲FMT活动覆盖了约10%的适应症患者。参与的中心表现出高安全标准和遵守国际共识指南。21家（68%）中心接受了卫生当局的正式或非正式监管。FMT是多发性、复发性CDI的广泛常规治疗和实验性治疗。FMT中心嵌入医院环境，在欧洲各地以高标准运营，提供安全的FMT。FMT覆盖率的巨大差距表明，需要提高临床意识，将欧洲的FMT活动增加至少10倍，以满足真正的、有指征的需求。NordForsk隶属于北欧理事会和创新基金丹麦（j.no. 8056- 00006 B）。
Faecal microbiota transplantation (FMT) is an emerging treatment modality, but its current clinical use and organisation are unknown. We aimed to describe the clinical use, conduct, and potential for FMT in Europe. We invited all hospital-based FMT centres within the European Council member states to answer a web-based questionnaire covering their clinical activities, organisation, and regulation of FMT in 2019. Responders were identified from trials registered at clinicaltrials.gov and from the United European Gastroenterology (UEG) working group for stool banking and FMT. In 2019, 31 FMT centres from 17 countries reported a total of 1,874 (median 25, quartile 10–64) FMT procedures; 1,077 (57%) with Clostridioides difficile infection (CDI) as indication, 791 (42%) with experimental indications, and 6 (0•3%) unaccounted for. Adjusted to population size, 0•257 per 100,000 population received FMT for CDI and 0•189 per 100,000 population for experimental indications. With estimated 12,400 (6,100–28,500) annual cases of multiple, recurrent CDI and indication for FMT in Europe, the current European FMT activity covers approximately 10% of the patients with indication. The participating centres demonstrated high safety standards and adherence to international consensus guidelines. Formal or informal regulation from health authorities was present at 21 (68%) centres. FMT is a widespread routine treatment for multiple, recurrent CDI and an experimental treatment. Embedded within hospital settings, FMT centres operate with high standards across Europe to provide safe FMT. A significant gap in FMT coverage suggests the need to raise clinical awareness and increase the FMT activity in Europe by at least 10-fold to meet the true, indicated need. NordForsk under the Nordic Council and Innovation Fund Denmark (j.no. 8056–00006B).
登录
查看更多内容
DOI：
10.1093/cid/ciaa948
发表时间：
2021-04-26
期刊：
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
影响因子：
--
作者：
Ghani R;Mullish BH;McDonald JAK;Ghazy A;Williams HRT;Brannigan ET;Mookerjee S;Satta G;Gilchrist M;Duncan N;Corbett R;Innes AJ;Pavlů J;Thursz MR;Davies F;Marchesi JR
通讯作者：
Marchesi JR
影响因子：
14.2
作者：
Debast, S. B.;Bauer, M. P.;Kuijper, E. J.
通讯作者：
Kuijper, E. J.
影响因子：
15.1
作者：
McCune, V. L.;Quraishi, M. N.;Hawkey, P. M.
通讯作者：
Hawkey, P. M.
影响因子：
3.7
作者：
Shin JH;Chaves-Olarte E;Warren CA
通讯作者：
Warren CA
影响因子：
24.5
作者：
Ianiro, Gianluca;Mullish, Benjamin H.;Cammarota, Giovanni
通讯作者：
Cammarota, Giovanni